drugset / Trial / NCT03214887
Autologous BMMNC Combined With HA Therapy for PAOD
Phase 1/2
Withdrawn
Academia Sinica, Taiwan
National Cheng-Kung University Hospital · collabNational Taiwan University Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of hyaluronan combined with autologous bone marrow mononuclear cells for the treatment of critical PAOD patients.
Timeline
- Start
- 2017-01-17
- Primary completion
- 2018-06-30
- Completion
- 2018-07-27
Outcome
Outcome not reported
Stopped (Enrollment): “Incomplete enrollment process”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RV-P1501 | Unknown | 10000 cells | — |
| Subject | RV-P1501 | Unknown | 100000 cells | — |
| Subject | RV-P1501 | Unknown | 1e+06 cells | — |